Loading...
Bilateral Trade Intelligence · $31.3K Total Trade · 2 Foreign Suppliers · 2 Indian Buyers · DGFT Verified · Updated March 2026
India imported $31.3K worth of pharmaceutical formulations from Guyana across 32 verified shipments, from 2 foreign suppliers to 2 Indian buyers. The top suppliers are DR BALWANT SINGHS HOSPITAL INC ($31.3K) and AI FARM ($1). The leading products are Sitagliptin ($5K) and Metformin ($4K). Average shipment value: $977.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Sitagliptin | $5.4K | 17.4% |
| 2 | Metformin | $3.9K | 12.3% |
| 3 | Nifedipine | $3.0K | 9.6% |
| 4 | Pantoprazole | $2.7K | 8.8% |
| 5 | Carvedilol | $2.0K | 6.4% |
| 6 | Sodium | $1.4K | 4.6% |
| 7 | Atorvastatin | $1.3K | 4.2% |
| 8 | Ofloxacin | $1.3K | 4.0% |
| 9 | Enalapril | $1.0K | 3.2% |
| 10 | Clindamycin | $970 | 3.1% |
| 11 | Diclofenac | $948 | 3.0% |
| 12 | Ciprofloxacin | $875 | 2.8% |
| 13 | Iron | $872 | 2.8% |
| 14 | Spironolactone | $872 | 2.8% |
| 15 | Prednisolone | $818 | 2.6% |
India imports 20+ pharmaceutical formulations from Guyana with a combined trade value of $31.3K. Key products include Sitagliptin ($5K), Metformin ($4K), Nifedipine ($3K), Pantoprazole ($3K), Carvedilol ($2K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 32 verified Indian Customs (DGFT) shipment records.
2 Indian pharmaceutical companies export finished formulations to Guyana. Leading exporters include Dr Balwant Singhs Hospital Inc, Ai Farm, . The top exporter accounts for 100.0% of total India–Guyana pharma exports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Guyana and India has experienced modest activity from 2022 to 2026. Over this period, India imported a total of $31,000 USD worth of finished pharmaceutical formulations from Guyana, distributed across 32 shipments. This indicates a consistent, albeit limited, engagement in the bilateral pharmaceutical trade. The average shipment value stands at approximately $977 USD, reflecting the niche nature of this trade route.
The primary supplier from Guyana is DR Balwant Singh's Hospital Inc., which has been responsible for all 31 shipments, offering a diverse range of 24 pharmaceutical products. The sole Indian buyer, Pandey Drug House, has consistently sourced these products, underscoring a stable demand for Guyanese pharmaceutical imports. This pattern suggests a specialized market segment where Guyanese pharmaceutical products cater to specific needs within India.
Guyana's contribution to India's overall pharmaceutical imports remains minimal. In 2024, India's total pharmaceutical imports were valued at $129.66 million USD, with Guyana accounting for a mere fraction of this amount. This underscores Guyana's limited role in India's expansive pharmaceutical import landscape. The imports from Guyana predominantly consist of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicating a focus on ready-to-use products rather than active pharmaceutical ingredients (APIs) or bulk drugs.
These are the top pharmaceutical products exported from India to Guyana, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Guyana buyers, regulatory requirements, and logistics for that specific product corridor. Products include Sitagliptin ($5K), Metformin ($4K), Nifedipine ($3K), Pantoprazole ($3K), Carvedilol ($2K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
2 companies in Guyana import pharmaceutical formulations from India. Top buyers include Pandey Drug House, Sri New Tech Milling Equipments, . The largest buyer accounts for 100.0% of India–Guyana pharma imports. Source: Indian Customs (DGFT).
Between 2024 and 2026, there have been no significant policy changes or trade agreements between India and Guyana specifically affecting pharmaceutical imports. The Central Drugs Standard Control Organisation (CDSCO) has maintained its existing regulatory framework for foreign pharmaceutical imports, with no major amendments impacting the Guyana-India trade corridor. Similarly, there have been no notable developments in regulatory harmonization efforts between the two countries during this period.
Registration process, GMP requirements, import documentation
For Guyanese pharmaceutical companies aiming to export products to India, obtaining registration with the CDSCO is mandatory. The process involves several key steps:
1. Application Submission: The Indian authorized agent submits an application through the CDSCO's SUGAM portal, providing details about the applicant, manufacturing site, and the products intended for import.
2. Documentary Requirements: Essential documents include a duly filled application form, a power of attorney from the foreign manufacturer, a site master file detailing the manufacturing facility, a free sale certificate from the country of origin, and a quality certificate such as ISO 13485.
3. Review and Approval: CDSCO reviews the application and may conduct inspections to verify compliance with Indian standards. Upon satisfactory evaluation, a registration certificate is issued, typically valid for three years.
The entire process can take several months, depending on the completeness of the application and the need for any additional information or inspections.
India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards as outlined by the World Health Organization (WHO). Manufacturers must provide a GMP certificate, which is a prerequisite for CDSCO registration. The CDSCO may also conduct inspections to ensure compliance with these standards. Additionally, a Certificate of Pharmaceutical Product (COPP) from the country of origin is often required to attest to the product's approval for sale in the destination country.
To import pharmaceutical products into India, the following documentation is essential:
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical products imported from Guyana to India are primarily finished formulations, with a notable emphasis on oral medications. The top ten products imported include:
1. Sitagliptin: $5,000 USD (17.4%)
2. Metformin: $4,000 USD (12.3%)
3. Nifedipine: $3,000 USD (9.6%)
4. Pantoprazole: $3,000 USD (8.8%)
5. Carvedilol: $2,000 USD (6.4%)
6. Sodium: $1,000 USD (4.6%)
7. Atorvastatin: $1,000 USD (4.2%)
8. Ofloxacin: $1,000 USD (4.0%)
9. Enalapril: $1,000 USD (3.2%)
10. Clindamycin: $970 USD (3.1%)
These products are commonly used in the treatment of chronic conditions such as diabetes, hypertension, and infections, indicating a focus on essential therapeutic areas.
The imports from Guyana to India predominantly consist of generic formulations of established drugs. There is a limited presence of innovator drugs, novel formulations, or advanced therapies in this trade corridor. This suggests that Guyana's pharmaceutical exports to India are primarily focused on meeting the demand for standard treatments rather than introducing cutting-edge medical innovations.
India's imports from Guyana are driven by several factors:
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
These tariffs and taxes are subject to change based on government policies and international trade agreements.
As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Guyana concerning pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations, but there are no bilateral agreements that offer preferential treatment for pharmaceutical products.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, allows for the rejection of patents on new forms of known substances unless they demonstrate enhanced efficacy. This provision has led to the production of generic versions of many patented drugs. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including imported drugs, to ensure affordability. Compulsory licensing provisions enable the government to allow the production of generic versions of patented drugs under certain conditions, further influencing the dynamics of pharmaceutical imports.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Guyana to India are typically transported via sea routes, with major ports such as Georgetown in Guyana serving as departure points. The transit time for sea freight can vary, generally ranging from 30 to 45 days, depending on the shipping line and specific routes taken. Air freight options are also available, offering faster delivery times but at a higher cost.
India exported pharmaceuticals worth $31.3K to Guyana across 32 verified shipments.
1. DR BALWANT SINGHS HOSPITAL INC — $31.3K. 2. AI FARM — $1. Total: 2 suppliers.
1. PANDEY DRUG HOUSE — $31.3K. 2. SRI NEW TECH MILLING EQUIPMENTS — $1. 2 buyers total.
1. Sitagliptin ($5.4K, 17.4%); 2. Metformin ($3.9K, 12.3%); 3. Nifedipine ($3.0K, 9.6%); 4. Pantoprazole ($2.7K, 8.8%); 5. Carvedilol ($2.0K, 6.4%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $31.3K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$977 per consignment across 32 shipments.
2 Indian companies. Largest: DR BALWANT SINGHS HOSPITAL INC with $31.3K.
TransData Nexus covers 2 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 32 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Exporters
2 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists